Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans and it is essential that new and better therapies are developed to treat this disease. Previous research suggests that casein kinase 2 (CK2), may be a promising therapeutic target for GBMs. CK2 has enhanced expression or activity in numerous cancers, including GBM and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models. Our studies demonstrate that the CK2 subunit, CK2α, is overexpressed in and plays an important role in regulating brain tumor initiating cells (BTIC) in GBM. Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2α had enhanced proliferation and anchorage-independent growth. Inhibition of CK2α using siRNA or small molecule inhibitors (TBBz, CX-4945) reduced cell growth and decreased tumor size and increased the survival rate in GBM xenograft mouse models. We also verified that inhibition of CK2α decreased the activity of a well-known GBM initiating cell regulator, β-catenin. Loss of CK2α decreased two β-cateninregulated genes that are involved in GBM initiating cell growth, OCT4 and NANOG. To determine the importance of CK2α in GBM stem cell maintenance, we reduced CK2α activity in primary GBM samples and tumor spheres derived from GBM patients. We discovered that loss of CK2α activity reduced the sphere forming capacity of BTIC and decreased numerous GBM stem cell markers including CD133, CD90, CD49f, and A2B5. Our study suggests that CK2α is involved in GBM tumorigenesis by maintaining BTIC through the regulation of β-catenin.
Introduction
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Four out of every 100,000 Americans are diagnosed with GBM, which represents ~15% of all primary brain tumors (1) . Once the diagnosis of GBM has been made, the overall median survival time for patients treated with surgery, radiation and chemotherapy is only 14 to 15 months (2) . The identification of GBM-associated cancer stem cells (CSCs) or GBMassociated brain tumor initiating cells (BTIC) has fueled research into the contributing role of this cell type in GBM pathogenesis and chemotherapy resistance (3) . The BTIC were shown to be capable of self-renewal and multi-lineage differentiation, they initiate tumor formation upon intracranial implantation within mice, and exhibit elevated therapeutic resistance relative to bulk glioma cells (4) . Therefore, elucidation of the molecular mechanisms underlying BTIC maintenance and proliferation offers new molecular targets for developing more effective GBM treatments.
An intriguing molecular target for GBM therapy is casein kinase 2 (CK2), which is a highly ubiquitous and conserved protein serine/threonine kinase composed of two catalytic subunits (CK2α or CK2α') and two regulatory subunits (CK2β) (5) . CK2 had increased protein expression or activity in the majority of cancers examined and its growth-related functions have been supported by the identification of a large number of growth-related proteins substrates (6) . CK2 is believed to be involved in GBM tumorigenesis, since inhibition of CK2 activity through small molecule inhibitors or siRNA induced apoptosis, and reduced growth in mouse xenograft models of human GBMs (7) (8) (9) (10) (11) . In addition, there is evidence suggesting that the CK2α subunit plays an important role in GBM. A genome-wide analysis of GBMs revealed an increase in the CK2α gene (CSNK2a1) (10) , and enhanced CK2α expression has been observed compared with pair-matched normal brain samples (12) .
In addition to its possible role in GBM tumorigenesis, there are recent reports indicating CK2α may play a role of BTIC maintenance and growth in GBM. For example, inhibition of CK2α was shown to impact the self-renewal capabilities of leukemia stem cells (13) and non-small cell lung carcinoma stem cells (14) . CK2α has also been shown to play an important role in neural stem cell proliferation and differentiation, indicating a potential role in BTIC in GBM (15) . Additionally, in vitro studies indicate that CK2α may also be involved in BTIC growth by controlling well known mediators of GBM including the Wnt/β-catenin pathway (16) (17) (18) .
To determine if CK2α does play an integral role in GBM tumorigenesis and in BTIC growth, we first generated immortalized GBM cell lines that had modulated CK2α expression. We verified that inhibition of CK2α using short interfering RNA (siRNA), short hairpin (shRNA), or small molecule inhibitors decreased growth, colony formation, and tumor size in mice. Moreover, we also discovered that an important regulator of BTIC in GBM, β-catenin, was decreased when CK2α activity was inhibited. We extended our findings to tumor spheres generated from GBM patients and determined that inhibition of CK2α decreased tumor sphere self-renewal, size, and in vivo tumorigenic potential of these cell lines. Through our work, we demonstrate for the first time that CK2α may play an important role in BTIC maintenance through the regulation of β-catenin in GBM.
Results

GBM patients with increased expression of CK2α may lead to a worse prognosis
Enhanced CK2α expression or activity has been observed in a variety of solid tumors including GBM. To verify that CK2α is overexpressed in GBM we analyzed primary samples from GBM patients. Consistent with previous reports, we discovered that 57% (4/7) of the GBM samples had a 2-to 5-fold increase in CK2α protein expression compared with normal brain samples (10;12) . We also conducted QPCR and verified that CK2α mRNA expression was enhanced in the same GBM patient samples (Fig. 1A and B) . To expand on our initial findings we also analyzed CK2α expression using the R2 microarray analysis and visualization platform (R2: microarray analysis and visualization platform (http:// r2.amc.nl)). We discovered that compared to an expression data set containing 172 normal brain sections, CK2α expression was significantly increased in a data set derived from 84 GBM samples (19) (Supplemental Fig. S1A ). We determined that the difference was statistically significant (p = 1.2×10 −10 ) using One Way Analysis of Variance (ANOVA). We also analyzed a data set that contained 101 tumor stem cells that were derived from GBM patients (20) (Supplemental Fig. S1A ). Consistently, we saw a reduction in CK2α expression in the normal brain data set when compared to the GBM data set that was statistically significant (p = 1.3×10 −8 ). We also conducted a preliminary prognosis analysis of CK2α expression in GBM patients using the Repository of Molecular Brain Neoplasia Data (Rembrandt). By sorting the GBM patients into high or low expression of CK2α, our findings suggest that GBM patients with high CK2α expression has a trend towards a worse prognosis compared with their low-expressing counterparts (Fig. 1C) . While our findings were not statistically significant (p = 0.08) we expanded our initial findings to The Cancer Genome Atlas (TCGA). We discovered that when the GBM patients were separated by subtype (classical, mesenchymal, neural, and proneural) only the mesenchymal subgroup had a statistically significant change (p = 0.034) in patient prognosis when comparing patients with high versus low CK2α expression (Fig. 1D) . The remaining subtypes did not have a statistically significant change in patient survival when the GBM patients were separated by CK2α expression (Supplemental Fig. S1B ).
CK2α is important in GBM tumorigenesis in vitro
To verify that CK2α is involved in GBM tumorigenesis, we modulated CK2 expression in two GBM cell lines, U87-MG and U138. We stably transduced YFP-tagged CK2α and CK2β using a retrovirus and verified the expression of each gene ( Fig. 2A) . The U87-MG cells transduced with CK2α exhibited enhanced cell growth and anchorage-independent growth, while exogenous expression of CK2β only enhanced cell growth compared with the YFP-transduced cells ( Fig. 2B and D) . We saw similar results in the U138 YFP-CK2α and YFP-CK2β transduced cells (Fig. 2C ). These findings suggest that CK2α overexpression, and to a lesser extent CK2β, increased GBM tumorigenic phenotypes. To confirm the importance of CK2α, we decreased both CK2α and CK2β expression 5-to 10-fold using siRNAs in both U87-MG and U138 cell lines (Fig. 3A) . We verified our siRNA specificity by monitoring the expression of the corresponding CK2 isoform. Little to no change was observed in CK2β expression when our cells were treated with siRNA to CK2α (siCK2α), as well as the reverse with siCK2β and CK2α expression (Fig. 3A) . While reducing either CK2 subunit decreased GBM cell growth, decreasing CK2α had a larger reduction in growth (Fig. 3B, Supplemental Fig. S2A ). In addition, only the reduction in CK2α inhibited anchorage-independent growth, confirming CK2α as a key regulator of GBM tumorigenisis (Fig. 3C) . We also conducted a dose-dependent assay using multiple small molecule CK2 inhibitors (TBBz and CX-4945) and found that inhibiting CK2 activity through these inhibitors also decreased GBM cell and anchorage-independent growth (Fig. 3D to F,  Supplemental Fig. S2B ). Our data are consistent with prior studies and taken together our preliminary data further confirm the importance of CK2α in GBM tumorigenesis.
CK2α is necessary for GBM tumorigenesis in vivo
We extended our study by testing the effects of reduction of CK2α expression on tumor formation, predicting that reducing endogenous CK2α expression would reduce the tumorigenicity of GBM cells. We generated an inducible shRNA to CK2α in U87-MG cells (U87 shCK2α). With doxycycline (Dox) induction (shCK2α+Dox), CK2α protein expression was reduced 3-to 4-fold compared with the uninduced control (shCK2α-Dox) and the uninfected cells induced with doxycycline (uninfect+Dox) (Fig. 4A ). Even though CK2α expression was decreased with doxycycline induction, we did not observe a change in CK2β levels, indicating that the shRNA to CK2α was specific (Fig. 4A) . The U87 shCK2+Dox cells consistently had significantly less cell growth compared with the shCK2α-Dox control cells (Fig. 4B) . Subsequently, we pretreated the U87-MG shCK2α cells with doxycycline and performed intracranial injections into NOD scid gamma mice. The mice were injected with 50,000 U87 shCK2α+Dox or shCK2α-Dox cells. We determined that the mice injected with the U87 shCK2α+Dox cells had significantly higher survival compared with the mice injected with U87 shCK2α-Dox cells, with the median survival time after tumor implantation increasing from 20 days to >40 days (P = 0.0009) (Fig. 4C) . To investigate tumor growth after implantation we harvested the mouse brains at 10 and 35 days and conducted hematoxylin and eosin staining to determine the growth of the tumors. At 10 days there was a significant reduction in tumor size and growth in the U87 shCK2α+Dox cells compared with the shCK2α-Dox controls (Fig. 4D) . A similar change was observed at 35 days as well (Fig. 4D) . We verified that CK2α protein and mRNA expression were reduced in the tumors derived from the U87 shCK2α+Dox cells compared with the shCK2α-Dox cells ( Fig. 4E and F ).
CK2α expression/activity regulates β-catenin transcriptional activity in GBM cells
We discovered in our GBM cell lines that β-catenin protein levels were reduced 2-to 3-fold only when CK2α expression was reduced using siCK2α and shCK2α (Figs. 3A and 4A ). To determine if the decrease in β-catenin protein levels significantly altered its transcriptional activity, we generated GBM cell lines that were stably transduced with a previously published Wnt/β-catenin GFP reporter construct (21) . This reporter plasmid has seven β-catenin/LEF-1 transcriptional response elements that precede GFP. Therefore when β-catenin is active it will transcribe GFP, and expression of GFP can be used to measure the transcriptional activity of β-catenin. U87-MG and U138 transduced with the GFP reporter treated with siRNA to CK2α exhibited a 2-to 3-fold reduction in both β-catenin expression and transcriptional activity as measured by GFP expression (Fig. 5A ). We also measured two β-catenin-regulated genes, OCT4 and NANOG. Conducting QPCR on the U87-MG siRNA-treated cells, we determined that cells deficient in CK2α, but not CK2β, had a 2-to 3-fold reduction in both OCT4 and NANOG mRNA (Fig. 5B ). To verify that CK2α inhibition decreased β-catenin transcriptional activity, we treated U87-MG and U138 transduced cell lines with the CK2α inhibitors TBBz or CX-4945. We found that inhibition of CK2α activity also resulted in a 2-to 3-fold decrease in β-catenin protein expression and a 2-to 10-fold decrease in its transcriptional activity as measured by GFP expression (Fig.  5C and D) . QPCR analysis of the treated cell lines also consistently showed a 2-fold decrease in OCT4 and NANOG ( Fig. 5E and F) . To determine if the β-catenin is a major signaling pathway by which CK2α can regulate GBM tumorigenesis, we stably transduced β-catenin in U87 shCK2α and U138 shCK2α cell lines. We verified that even after Dox treatment, resulting in a 2-to 3-fold reduction in CK2α expression, β-catenin expression was increased to similar levels as the cell lines not treated with Dox (Fig. 5G ). Upon reintroduction of β-catenin we discovered that cell growth and anchorage independent growth in cells lacking CK2α expression was rescued to levels similar to cell lines not treated with Dox ( Fig. 5H-J) . The canonical Wnt/β-catenin signaling was shown to play a key role in the regulation of tissue self-renewal (22) and has been well studied in BTIC in GBM. In addition, OCT4 and NANOG were both previously found to regulate BTIC growth (23) . Our findings suggest that CK2α may be involved in maintaining BTIC through the regulation of β-catenin.
Inhibiting CK2α activity in GBM tumor spheres reduces β-catenin activity
To explore the significance of CK2α in BTICs, we generated multiple GBM tumor spheres cell lines from GBM patient samples. Tumor spheres have become widely accepted as a method for culturing cells that are enriched for cells that are capable of self-renewal and tumor initiation from primary GBM (24) . We initially verified that our GBM tumor spheres were enriched for BTIC by monitoring CD133 expression. Using FACS, we determined that our tumor spheres were enriched for CD133+ cells (75% to 95%) compared with the isotype control, indicating that our tumor spheres were enriched for BTIC (Fig. 6A ). Further analysis of the CD133+ subpopulation showed that CK2α mRNA expression was not significantly different compared to the CD133− group (Supplemental Fig. S3 ). We also compared the CD15+ and CD15− subpopulations and did not observe a significant difference. This finding was consistent with previously published findings and were not too surprising since CK2α has been shown to play an integral role in a variety of cellular processes including: regulating proliferation/apoptosis balance, the UPR (unfolded protein response), rRNA synthesis, and spliceosome functions (25) . To determine if CK2α is important in BTIC we generated tumor spheres that upon doxycycline induction would express shRNAs specific to CK2α (shCK2α+Dox). We determined that induction of doxycycline reduced CK2α protein expression 3-fold and mRNA expression 2-fold compared with the uninduced tumor spheres (shCK2α-Dox) or the control tumor spheres that were not infected but were treated with doxycycline (uninfect+Dox). There was no change in CK2β protein expression indicating that our shRNA was specific to CK2α (Fig.  6B) . Consistent with our previous findings, we also observed a 2-to 3-fold decrease in β-catenin levels and a 2-fold reduction in OCT4 and NANOG mRNA levels in the shCK2α +Dox tumor spheres compared with the control tumor spheres (Fig. 6B and C) . The tumor spheres were also treated with the CK2 inhibitor, CX-4945. We determined that inhibiting Nitta et al.
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CK2 activity also reduced β-catenin protein expression 3-fold and reduced the transcriptional activity of β-catenin as measured by the Wnt/β-catenin GFP reporter by 2-to 6-fold ( Fig. 6D and E) . Consistently, OCT4 and NANOG mRNA expression was also decreased 2-to 3-fold (Fig. 6F ). To confirm these findings, we analyzed an additional tumor sphere cell line (TS #2). Consistent with our previous results we discovered a dosedependent response to CX-4945 in the TS#2 spheres resulting in a 5-fold reduction of β-catenin expression and a 5-to 10-fold reduction in NANOG and OCT4 expression (Supplemental Fig. S4A and B).
CK2α plays an important role in maintaining BTIC in GBM
To determine if CK2α plays an important role in BTIC we first determined if CK2α inhibition reduced the number of BTIC in our tumor spheres by analyzing the GBM stem cell marker CD133. Upon CX-4945 treatment we observed a shift in the FACS profiles indicating that the subpopulation of CD133+ cells was reduced ~80% (Fig. 7A ). Since CD133 is still a controversial GBM stem cell marker, we also analyzed an additional freshly dissociated GBM tumor sphere line (passage <5) for additional neural stem cell markers: CD15, A2B5, CD49f, and CD90 (26) (Fig. 7B ). Our FACS analysis showed that in low passage tumor spheres both 5μM and 10μM CX-4945 treatment reduced the CD15+ subpopulation by ~50% and A2B5+ cells by ~70% (Fig. 7B) . We also observed a decrease in the CD49f+ and CD90+ cells by 22% and 23%, respectively (Supplemental Fig 5) . Consistent with our previous data the low passage tumor spheres had a reduction in CD133+ cells (Supplemental Fig. 4 ). To determine if the decrease in GBM stem cell markers was functionally significant we analyzed stem cell phenotypes in our tumor spheres transduced with shRNA to CK2α. We discovered that the shCK2α+Dox tumor spheres had a significantly reduced size compared with the shCK2α-Dox spheres (Fig. 7C ). In addition, decreasing CK2α expression reduced the number of tumor spheres that formed, ~2-fold compared with the shCK2α-Dox tumor spheres, and ~10-fold when treated with the CK2 inhibitors, TBBz or CX-4945 (Fig. 7D) . We also determined the frequency of sphereinitiating cells by performing a limited dilution assay (LDA) (27) . The shCK2α+Dox tumor spheres had a significant decrease in the in vitro sphere-forming capacity of the cells (1/3,432) compared with the shCK2α-Dox tumor spheres (1/301) or the uninfected spheres treated with Dox (1/301) (P = 0.009) (Fig. 7E) . We also consistently discovered a dosedependent effect when the tumor spheres were cultured with CX-4945. Compared with the DMSO control (1/83), 5 μM CX-4945 reduced the sphere forming capacity of the spheres 13-fold (1/1,100), while 10 μM had a 200-fold reduction (1/16,884) (P = 0.005 and P = 0.0007) (Fig. 7E) . To verify our findings, we analyzed the TS #2 cell line and determined that the sphere-forming capacity was reduced in the CX-4945 (1/1846) and TBBz treated spheres (1/1250) compared to the DMSO control spheres (1/30)(P = 0.0002) (Supplemental Fig. S4C ). We also determined that the TS#2 spheres had reduced proliferation and sphere size when treated with CX-4945 (Supplemental Fig. S4D and E). These findings are consistent with our work and provide additional support showing that CK2α plays an integral role in maintaining BTIC growth.
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Discussion
Recent evidence suggests that CK2 is involved in maintaining a subpopulation of cells in the tumor that is responsible for initiating and maintaining tumor growth. This BTIC subpopulation is capable of self-renewal, asymmetric division, and multi-lineage differentiation (28;29) , and current evidence suggests that it is necessary (and sufficient) to eradicate BTICs for therapeutic efficacy in multiple forms of cancer (30;31 ). Here we demonstrate for the first time that decreasing CK2α expression or reducing its activity through small molecule inhibitors decreases the BTIC subpopulation in GBM. Using GBM tumor spheres derived from patients, we determined that loss of CK2α resulted in a decrease in OCT4 and NANOG, two β-catenin-regulated genes associated with BTICs (23). Oct4 was shown to play an essential role in maintaining the stem cell properties of BTIC through Sox2 expression (32), while NANOG modulated GBM stem cell clonogenicity and proliferation (33) . The loss of these BTIC regulators resulted in a loss of GBM "stemness" as evident through the decrease in tumor sphere size, growth, and sphere-forming capacity (Figure 8) . Together, our findings show for the first time that targeting CK2α not only decreases GBM tumorigenicity, but can also deplete the BTIC subpopulation making it an intriguing therapeutic target for GBM.
The mechanism by which CK2α can regulate β-catenin activity has been well studied in other tumor types, but is currently unknown in GBM. In vitro mapping studies identified the Thr393 site in the central armadillo repeat domain of β-catenin as a key site regulating β-catenin proteasomal-dependent degradation (34). Additionally, CK2α was shown to regulate β-catenin indirectly. CK2α was found to phosphorylate and inhibit AKT/protein kinase B, known activators of β-catenin (35;36), and phosphorylate α-catenin at Ser641 thereby preventing the inhibitory effects of α-catenin on β-catenin (37). These studies suggest that CK2α may positively regulate β-catenin activity directly or indirectly, but additional studies are needed to determine the exact mechanism by which CK2α can regulate β-catenin activity in BTICs.
While we demonstrated that CK2α can regulate β-catenin, there are other pathways that CK2α could potentially regulate in maintaining BTICs. For instance, CK2α has been linked to the hedgehog (HH)/Gli1 and Notch pathways. The HH pathway was shown to regulate self-renewal, growth, and survival of BTIC (38) , and regulate key factors in maintaining GBM tumor initiating cells including: Bmi1 (39-41) and ABCG2 (42) . Notch signaling was also shown to play critical roles in GBM stem cell survival and self-renewal (43-45). Interestingly, CK2α was shown to regulate both pathways in lung cancer. Inhibition of CK2α using small molecule inhibitors reduced expression and activity of Gli1, which altered ABCG2 expression that led to a reduction in the BTIC-like side population in lung cancer cells (46) . Decreasing CK2α expression using siRNA resulted in a reduction in Notch transcriptional activity that resulted in a reduction in the stem cell subpopulation (47) . These reports combined with our findings suggest that CK2α may influence multiple pathways in GBM initiating cell maintenance suggesting that inhibition of CK2α could yield better therapeutic effects than using HH or Notch inhibitors alone.
While a great deal of research has been conducted to generate a CK2α inhibitor for cancer therapy, there is only one molecule that is currently being tested for clinical trials. CX-4945 is a CK2α small molecule adenosine triphosphate-binding site inhibitor that possesses a high bioavailability and is currently in phase I clinical trials (48) . Through our work and that of others, CX-4945 treatment has been shown to decrease cell adhesion, migration, and cell cycle progression, while also inducing apoptosis in immortalized and primary GBM samples (49) . Past studies also demonstrate that CX-4945 treatment significantly inhibits tumor growth and increases median survival time when GBM cells are injected subcutaneously into the flank or intracranially in a mouse xenograft model (50) . Our findings expand on these initial reports by demonstrating that CX-4945 could decrease GBM initiating cell growth and stemness through β-catenin. We found that in GBM tumor spheres CX-4945 had a dose-dependent response resulting in a decrease in β-catenin expression, β-cateninregulated genes (OCT4 and NANOG), and GBM stemness. Taken together, our findings indicate that targeting CK2α using CX-4945 could be a powerful therapeutic treatment for GBM patients due to the role of CK2α in maintaining numerous pathways necessary for GBM tumorigenesis and BTIC growth. Additional clinical studies should be conducted to determine the efficacy of CX-4945 in GBM.
Materials and Methods
Cell culture and primary tissue samples
The GBM cell lines U87-MG and U138 (American Type Culture Collection, Manassas, Virginia, USA) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum and 2 mM L-glutamine. Cells were transfected using Effectene (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Tumor spheres were derived from primary GBMs and cultured in a tumor stem base medium previously shown to enrich for GBM stem cells (24) . Our tumor sphere medium consisted of neurobasal medium containing B27-A, 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast growth factor, and 20 μg/mL heparin. The seven GBM tissue samples were harvested from primary GBM patients and the tissue was immediately frozen in dry ice. The normal brain was harvested from temporal lobe of a patient undergoing anterior temporal lobectomy for removal of mesial temporal sclerosis. The tissue was immediately frozen in dry ice and later thawed for harvesting of protein lysate.
Western blot
For protein analysis, protein extracts from cells were harvested and immunoblotted as previously described (51) . The following antibodies were used for immunoblotting: green fluorescent protein (GFP), CK2α, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (all from Cell Signaling Technology, Danvers, MA, USA), and CK2β (Millipore, Hayward, CA, USA). Chemiluminescence signals were quantitated using NIH Image J (National Institutes of Health, Bethesda, MD, USA). 
RNA interference
Retroviral and lentiviral infections
The retrovirus pMSCV-YPet was generated by subcloning YPet from the pCEP4-YPet plasmid into the pMSCV backbone (52) . Retroviral infections were carried out as previously described except that the Phoenix-Ampho cell lines were used instead of HEK293 cells (51) . Thirty-six hours after infection of the U87-MG or U138 cells, the cells were selected by culturing for 2 days in selective medium containing 0.5 μg/mL puromycin. The doxycycline inducible plasmid, pTRIPZ Retroviral shRNA, to CK2α was purchased commercially (Thermo Scientific, Waltham, MA, USA). Retroviral infections were carried out as described above, but the packaging plasmids, psPAX2 and pMD2.G, were transfected into HEK293 cells in neurobasal medium. Thirty-six hours after infection, the cells were selected using 5μg/ml puromycin for 3 days.
Cell growth analysis
U87-MG-and U138-infected cells were plated in six-well plates (5 × 10 5 cells per well) and cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 units per ml penicillin/streptomycin. The number of live cells was counted at the specified times by means of trypan blue exclusion assay. Four sets of cells were counted per time point. Upon treatment with CK2 inhibitors (CX-4945 and TBBz), DMSO was used as a vehicle control. The amount of DMSO that was added was equal to the highest concentration of the drug, resulting in a final DMSO concentration of 0.01%. Experiments were done in triplicate and results are expressed as mean ± SD. To determine if the growth was statistically significant we used the Mann-Whitney U test. Tumor spheres were plated in a 96-well plate (100 cells per well) and cultured as described previously. After 14 days the number of spheres that formed were counted per well. Experiments were done in triplicate and results are expressed as mean ± SD. The Mann-Whitney U test was conducted to determine statistical significance.
Soft agar assay
U87-MG-infected cells were plated in six-well plates (3 × 10 5 cells per well) and suspended in DMEM as previously described (51) . The presence of colonies was scored after 10 days using Genetools software (Syngene, Los Altos, CA, USA). Experiments were done in triplicate and results are expressed as mean ± SD. The Mann-Whitney U test was conducted to determine statistical significance.
Quantitative real-time-PCR analysis
All specimens were accrued and evaluated under institutional review board (IRB)-approved protocols. Total RNA from each cell line was extracted using Trizol reagent (Promega, Sunnyvale, CA, USA) according to the manufacturer's protocol. The reverse transcription and quantitative PCR (QPCR) were carried out using the Brilliant II Syber Green QRT-PCR Master Mix Kit according to the manufacturer's protocol (Stratagene, Santa Clara, CA, USA). Primers were designed specifically for the CK2 genes and the specificity was verified by sequencing. Their sequences were: CK2α (forward), 5′-GGTTGTATGCTGGCAAGTATGA-3′; CK2α (reverse), 5′-TCGAGAGTGTCTGCCCAAGAT-3′; CK2β (forward), 5′-TGAGCAGGTCCCTCACTACC-3′; CK2β (reverse), 5′-GTAGCGGGCGTGGATCAAT-3′; Nanog (forward), 5′-ACCAGAACTGTGTTCTCTTCCACC -3′; Nanog (reverse), 5′-CCATTGCTATTCTTCGGCCAGTTG-3′; and Oct4 (forward), 5′-GGAAGGTATTCAGCCAAACGACCA-3′; Oct4 (reverse), 5′-CTCACTCGGTTCTCGATACTGGTT -3′; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward) 5′-GTCCACCACCCTGTTGCTGTA-3′; GAPDH (reverse) 5′-ACCACAGTCCATGCCATC-3′. Relative copy number was determined using the comparative C t method. GAPDH served as the normalizing control. The Mann-Whitney U test was conducted to determine statistical significance.
Sphere formation
Following digestion of primary tumor to single cells, the single cells were plated at limiting dilutions or at a density of 100 cells per well. Cells were cultured in neurobasal medium containing B27-A, epidermal growth factor, basic fibroblast growth factor, and heparin. For estimation of sphere initiating cell frequency, limiting dilution analysis (LDA) was done as described previously (53) . Cultures were carried out for 14 days and scored for wells that did not have spheres. An extreme LDA algorithm was used to determine the frequency of sphere initiating cells (27) . Each experiment was done in triplicate and analyzed using 2-sided t tests. To determine sphere growth, 100 cells per well were plated and the cultures were carried out for 14 days. The number of spheres per well was counted and analyzed using 2-sided t tests.
Tumor formation
Cells were resuspended in a 1:1 mixture of cold PBS and Matrigel (BD Biosciences, San Jose, CA, USA) and adjusted to the appropriate concentration. One hundred microliters of the cell suspension was injected into the cortex of 6-to 8-week-old NOD scid gamma mice. Mice were sacrificed at 10 and 40 days and the tumors were extracted. Tumor size after injection was analyzed by fixing the tumors in paraformaldehyde, sectioning, and staining with hematoxylin and eosin. The mice were sacrificed under approved Institutional Animal Care and Use Committee protocols.
CK2 inhibitors
TBB, TBBz, and CX-4945 (Sigma, St. Louis, MO, USA) were used in inhibitor studies at the following concentrations for the specified time: 10 to 100 μM (TBB), 6 to 25 μM (TBBz), and 1 to 10 μM (CX-4945). Typically, U87-MG and U138 cells were incubated for 5 days with each compound and then analyzed. Fifty percent of the medium was replaced every 3 days with fresh medium containing treatment compounds at the original concentrations. Controls were treated with the vehicle control, dimethyl sulfoxide (DMSO;
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Sigma, St. Louis, MO, USA). The amount of DMSO added was equal to the highest concentration of drug, resulting in a final concentration of 0.01%.
Flow cytometry
Before flow cytometry analysis or sorting, cells were dissociated as described above or washed and dissociated using TrypLE (Gibco, Carlsbad, CA, USA). Cells were resuspended in a 100μL staining volume of fluorescence activated cell sorting (FACS) buffer (Hanks' balanced salt solution + 0.1% bovine serum albumin) and kept on ice. The following antibodies were used: CD133/1, and CD133/2 biotin (Miltenyi Biotech, San Diego, CA, USA), CD90 (Biolegend, San Diego, CA, USA), CD15 (BD Bioscience, San Jose, CA, USA), CD49f (BD Bioscience, San Jose, CA, USA), AB25 (Miltenyi Biotech, San Diego, CA, USA) and PE-CY7 strep (BD Biosciences, San Jose, CA, USA). All analyses were conducted using a LSR II FACS machine (BD Biosciences, San Jose, CA, USA) or sorted on an ARIA-II (BD Biosciences, San Jose, CA, USA) at the Stanford University FACS facility. Appropriate isotype controls were used to control for nonspecific isotype background.
GBM Survival Curve
The Kaplan Meier survival curve for GBM was derived using the National Cancer Institute REMBRANDT and the TCGA data source. The GBM patients were separated into high or low CK2α expression and graphed according to patient survival. The survival curves were derived using the http://genepyramid.stanford.edu/microarray/Explore/ and the R2: microarray analysis and visualization platform (http://r2.amc.nl). A log-rank test was used to determine the p value. Increased CK2α expression may lead to a worse prognosis for GBM patients. A, Western blot measuring the fold change in CK2α in seven primary GBM samples compared with normal brain (NB). GAPDH was used to control for protein load. B, QPCR analysis of primary GBM samples. *-represents samples with higher expression of CK2α. C. Survival curve for all GBM patients with high or low expression of CK2α using the REMBRANDT database. D. Survival curve for the mesenchymal subtype of GBM patients with high or low expression of CK2α using the TCGA. Reducing expression or inhibiting CK2α activity decreased GBM tumorigenesis in vitro. A, siRNAs specific to CK2α (siCK2α) and CK2β (siCK2β) were introduced into U87-MG and U138 cells. A scrambled nonspecific siRNA (siScr) was used as a control. Reducing expression of CK2α using shRNA decreased GBM tumorigenesis in vivo. A, shRNAs specific to CK2α (shCK2α) were introduced through lentiviral infections into U87-MG cells. 5 μg/mL of Dox was used to induce expression of shRNA (shCK2α+Dox). The uninduced infected cells (shCK2α-Dox) and uninfected cells treated with Dox (uninfect +Dox) were used as controls. The numbers under each blot correspond to the fold change in protein levels relative to the uninfected control. B, cell growth analysis of U87-MG infected with shCK2α. *represents a statistically significant change from the control, P < 0. Oncogene. Author manuscript; available in PMC 2016 January 01.
